lamotrigine has been researched along with Refractory Depression in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Lamotrigine is currently considered at best only as second line augmentation for treatment-resistant unipolar depression while its clinical efficacy and safety profiles remain inconclusive." | 9.01 | Lamotrigine augmentation in treatment-resistant unipolar depression: A comprehensive meta-analysis of efficacy and safety. ( Chen, CH; Chiu, YH; Goh, KK; Lu, ML, 2019) |
| " Lamotrigine is currently considered at best only as second line augmentation for treatment-resistant unipolar depression while its clinical efficacy and safety profiles remain inconclusive." | 5.01 | Lamotrigine augmentation in treatment-resistant unipolar depression: A comprehensive meta-analysis of efficacy and safety. ( Chen, CH; Chiu, YH; Goh, KK; Lu, ML, 2019) |
| "The diagnoses were major depressive disorder (n = 15), bipolar I disorder (n = 6), and bipolar II disorder (n = 16)." | 2.82 | Prediction of an Optimal Dose of Lamotrigine for Augmentation Therapy in Treatment-Resistant Depressive Disorder From Plasma Lamotrigine Concentration at Week 2. ( Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Suzuki, T, 2016) |
| "The diagnoses were major depressive disorder (n = 39), bipolar I disorder (n = 10), and bipolar II disorder (n = 35)." | 1.56 | A High Plasma Lamotrigine Concentration at Week 2 as a Risk Factor for Lamotrigine-Related Rash. ( Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Suzuki, T, 2020) |
| "The diagnoses were major depressive disorder (n = 19), bipolar I disorder (n = 6), and bipolar II disorder (n = 22)." | 1.46 | Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder. ( Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Suzuki, T, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Suzuki, T | 6 |
| Mihara, K | 6 |
| Nagai, G | 6 |
| Kagawa, S | 6 |
| Nakamura, A | 6 |
| Nemoto, K | 6 |
| Kondo, T | 6 |
| Goh, KK | 1 |
| Chen, CH | 1 |
| Chiu, YH | 1 |
| Lu, ML | 1 |
| Chan, HN | 1 |
| Mitchell, PB | 1 |
| Loo, CK | 1 |
| Harvey, SB | 1 |
| Barbee, JG | 1 |
| Thompson, TR | 1 |
| Jamhour, NJ | 1 |
| Stewart, JW | 1 |
| Conrad, EJ | 1 |
| Reimherr, FW | 1 |
| Thompson, PM | 1 |
| Shelton, RC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Lamotrigine as an Antidepressant Augmentation Agent in Treatment Refractory Unipolar Depression[NCT00901407] | 138 participants (Actual) | Interventional | 2003-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for lamotrigine and Refractory Depression
| Article | Year |
|---|---|
Lamotrigine augmentation in treatment-resistant unipolar depression: A comprehensive meta-analysis of efficacy and safety.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Met | 2019 |
Pharmacological treatment approaches to difficult-to-treat depression.
Topics: Anticonvulsants; Antidepressive Agents; Comorbidity; Depressive Disorder, Treatment-Resistant; Disea | 2013 |
2 trials available for lamotrigine and Refractory Depression
| Article | Year |
|---|---|
Prediction of an Optimal Dose of Lamotrigine for Augmentation Therapy in Treatment-Resistant Depressive Disorder From Plasma Lamotrigine Concentration at Week 2.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Chromatograp | 2016 |
A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Depres | 2011 |
5 other studies available for lamotrigine and Refractory Depression
| Article | Year |
|---|---|
A High Plasma Lamotrigine Concentration at Week 2 as a Risk Factor for Lamotrigine-Related Rash.
Topics: Antipsychotic Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Exanthem | 2020 |
Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Depressive Disord | 2017 |
Relationship Between UGT1A4 and UGT2B7 Polymorphisms and the Steady-State Plasma Concentrations of Lamotrigine in Patients With Treatment-Resistant Depressive Disorder Receiving Lamotrigine as Augmentation Therapy.
Topics: Adult; Anticonvulsants; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Female; | 2019 |
Relationship between plasma concentrations of lamotrigine and its early therapeutic effect of lamotrigine augmentation therapy in treatment-resistant depressive disorder.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Ad | 2014 |
Lamotrigine augmentation therapy in a case with treatment-resistant unipolar depression that showed insufficient response to electroconvulsive therapy.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Electroc | 2016 |